15th ESO-ESMO Masterclass in Clinical Oncology

Chairs: N. Pavlidis, GR - R.A. Stahel, CH
Scientific Co-ordinators: W. Gatzemeier, IT - R. Popescu, CH

AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical or clinical oncologists who wish to improve their skills or those who are preparing for the national board exam.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-oriented training. The programme focuses on breast, colorectal, lung, genito-urinary, gynaecological, head and neck cancers.
Spotlight sessions will facilitate compact update on communication skills, physical activity, biology of cancer, bone health, immunotherapy, melanoma, advanced oncology nursing practice, cancer in the 3rd world, health economics, cancer of unknown primary, new oncological emergencies, brain tumours, treatment of elderly cancer patients, genetic counselling, haematological diseases (focus on lymphomas and myeloma), sarcomas and GIST, supportive care (mucositis and skin toxicity), cancer and pregnancy.
 

TEACHING FORMAT
The Masterclass offers plenary lectures regarding state-of-the-art clinical evaluation and treatments with reference to clinical guidelines and which will conclude in take-home messages. Participants will deliver case presentations within tumour boards and small groups and discuss them with the chairmen and the faculty. Informal discussion will be facilitated during the aperitifs with the expert.
All participants will reside at the course venue and participation is compulsory throughout the course. The Masterclass will be entirely in English and fluency in English is necessary for admission. Participants of the concomitant Masterclass in Nursing Oncology will attend selected medical sessions whilst the communication skills sessions will be attended jointly.


THE MASTERCLASS IS:
• A 5-day residential educational event
• Full immersion
• Clinically- oriented
• Multidisciplinary
• An international faculty of top experts delivering lectures focusing on genito-urinary, breast, gynaecological, head and neck, gastro-intestinal and lung cancers.

 

The Masterclass in Clinical Oncology is an ESO-ESMO joint event
The Masterclass is held in collaboration with the Flims Alumni Club
The 2016 Masterclass is part of the Masterclass-Online Study Program in Advanced Oncology of the University of Ulm

ORGANISING SECRETARIAT
Francesca Marangoni
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Ph: +39 02 85464525
Fax: +39 02 85464545
Email: fmarangoni@eso.net

Applications:
Corinne Hall
Ph: +39 02 85464522
Email: chall@eso.net


ACCREDITATION
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.
The event is designated for a maximum of 29 European CME credits (ECMEC).
Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Furthermore, the conference has been accredited with 25 ESMO-MORA category 1 points.


SOCIAL MEDIA
Tweet, network and follow updates using #16MCO on Twitter and Facebook.

Would you like to see what last year’s participants got up to? Take a look at a Storify we created with comments and pictures from the 2015 Masterclass.

 

ACKNOWLEDGEMENTS
The Masterclass is part of the Sharing Progress in Cancer Care programme whose sustaining members are (as of July 2015):

 

• Gold members: BMS, Eli Lilly, Genomic Health, Helsinn, Merck Serono, Pfizer and Roche
• Silver members: Bayer, Boehringer Ingelheim, Celgene Corporation, Novartis Oncology, Sandoz and Sanofi

FACULTY
M. Aapro, Clinique de Genolier, Dept. of Oncology, Genolier, CH
A. Arber, University of Surrey, Faculty of Health and Medical Sciences, Guildford, UK
J. Bernier, Clinique de Genolier, Dept. of Radiotherapy, Genolier, CH
P. Casali, National Cancer Institute, Dept. of Medical Oncology, Milan, IT
A. Cervantes, Hospital Clinico Universitario, Dept. of Medical Oncology, Valencia, ES
G. Curigliano, European Institute of Oncology, Div. of Medical Oncology, Milano, IT
A. Dietz, University Hospital Leipzig, ENT Department, Leipzig, DE
T. Eisen, University of Cambridge, Dept. of Oncology, Cambridge, UK
C. Faivre-Finn, The Christie NHS Foundation Trust, Dept. of Clinical Oncology, Manchester, UK
K. Fizazi, Institut Gustave Roussy, Dept. of Cancer Medicine, Villejuif, FR
W. Gatzemeier, Humanitas Cancer Center, Breast Unit, Rozzano, IT
M. Ghielmini, Oncology Institute of Southern Switzerland (IOSI), Div. of Medical Oncology, Bellinzona, CH
S. Gillessen, Kantospital St. Gallen, Onco-Haematology Clinic, St Gallen, CH
S. Hillinger, University Hospital Zurich, Dept. of Thoracic Surgery, Zurich, CH
A. Horwich, The Royal Marsden Hospital - Institute of Cancer Research, Div. of Radiotherapy and Imaging, Sutton , UK
A. Hoy, Consultant in Palliative Medicine, Esher, Surrey, UK
R. Huddart, The Institute of Cancer Research (ICR) - Royal Marsden Hospital, Div. of Radiotherapy and Imaging, Sutton, Surrey, UK
O. Michielin, Lausanne University Hospital - CHUV, Dept. of Medical Oncology, Lausanne, CH
O. Pagani, Oncology Institute of Southern Switzerland (IOSI), Breast Unit, Bellinzona, CH
N. Pavlidis, University Hospital of Ioannina, Div. of Medical Oncology, Ioannina, GR
F.A. Peccatori, European Institute of Oncology, Div. Gynecologic Oncology, Milano, IT
B. Pestalozzi, University Hospital, Oncology Clinic, Zurich, CH
S. Peters, Centre Hospitalier Universitaire Vaudois, Dept. of Oncology, Lausanne, CH
R. Popescu, Hirslanden Klinik Aarau, Tumor Center - Dept. of Medical Oncology, Aarau, CH
D. Sebag-Montefiore, St James' Institute of Oncology - St James' University Hospital, Dept. of Medical Oncology, Leeds, UK
C. Sessa, Oncology Institute of Southern Switzerland (IOSI), Div. of Medical Oncology, Bellinzona, CH
R.A. Stahel, University Hospital Zurich, Clinic for Oncology, Zurich, CH
S. Stoll, University Hospital Zurich, Clinic for Oncology, Zurich, CH
T. Szucs, Basel University, Institute of Pharmaceutical Medicine, Basel, CH
E. van Cutsem, University Hospital Gasthuisberg, Dept. Internal Medicine - Digestive Oncology Unit, Leuven, BE
J.B. Vermorken, University Hospital Antwerp, Dept. of Medical Oncology, Edegem, BE
M. Weller, University Hospital Zurich, Dept. of Neurology, Zurich, CH
Y. Wengström, Karolinska University Hospital, Stockholm, SE

 12 March

		Participants' arrival, airport transfers, registration
12:30		Lunch
13:45		Focus on ESO, ESMO and EONS F.A. Peccatori, IT - R.A. Stahel, CH - A. Margulies, CH
		PARALLEL SESSIONS
14:15		Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK
14:15		Warm up + Case presentations by participants R.A. Stahel, CH - R. Popescu, CH
15:45		Coffee break
16:00		Communication Skills Workshop - 2 Groups  A. Arber, UK - A. Hoy, UK
16:00		Warm up + Case presentations by participants N. Pavlidis, GR - R. Popescu, CH
17:30		Coffee break
17:45		Communication Skills Workshop - 2 Groups A. Arber, UK - A. Hoy, UK
17:45		Warm up + Case presentations by participants  N. Pavlidis, GR - R.A. Stahel, CH
20:00		Dinner

 

 13 March

8:30		Spotlight session Immunotherapy    O. Michielin, CH
9:00		Spotlight session Melanoma    O. Michielin, CH
9:30		Spotlight session State of the art approaches to brain tumours    M. Weller, CH
10:00		Spotlight session Physical activity / exercise and Cancer    Y. Wengström, SE
11:00		Clinical session Lung cancer I    Chair: R.A. Stahel, CH
		Surgery    S. Hillinger, CH Radiotherapy    C. Faivre-Finn, UK NSCLC systemic therapy     R.A. Stahel, CH Discussion
13:00		Lunch
14:00		Clinical session Lung cancer II    Chair: R.A. Stahel, CH
		Small cell lung cancer    C. Faivre-Finn, UK Discussion
14:30		Tumour board Lung cancer    R.A. Stahel, CH - S. Hillinger, CH - C. Faivre-Finn, UK
15:30		Spotlight session Biology of cancer    S. Peters, CH
16:00		Spotlight session Bone health and cancer    S. Peters, CH
18:30		Aperitif with the expert Lung cancr
19:30		Dinner

 

 14 March

8:30		Spotlight session Cancer of unknown primary    N. Pavlidis, GR
9:00		Spotlight session New oncological emergencies    B. Pestalozzi, CH
9:30		Spotlight session Key points on how to write a scientific paper/review    M. Aapro
10:00		Spotlight session Treatment of elderly cancer patients    M. Aapro, CH
10:30		Coffee break
11:00		Clinical session Genito-urinary cancers I    Chair: A. Horwich, UK
		Hormone therapy for prostate cancer    A. Horwich, UK Endocrine resistant - refractory prostate cancer    K. Fizazi, FR Current controversies on testicular tumours    R. Huddart, UK Metastatic renal cancer: evidence-based treatment    T. Eisen, UK Discussion
13:00		Lunch
14:00		Clinical session Genito-urinary cancers II    Chair: A. Horwich, UK
		Treatment of Bladder cancer    R. Huddart, UK Discussion
14:30		Tumour board Genito-urinary cancers     K. Fizazi, FR - A. Horwich, UK - R. Huddart, UK - T. Eisen, UK
15:30		Spotlight session The APCCC (Advanced Prostate Cancer Consensus Conference)    S. Gillessen, CH
16:00		Spotlight session Demands on the cancer workforce and the need for innovation   D. Kelly, UK
16:30		Spotlight session Health economics    T. Szucs, CH
18:30		Aperitif with the expert GU Cancers
19:30		Dinner

 

 15 March

8:30		Spotlight session Genetics/Genetic counselling    S. Stoll, CH
9:00		Spotlight session Haematological diseases - focus on lymphomas and myeloma    M. Ghielmini, CH
9:45		Spotlight session Sarcomas and GIST     P. Casali, IT
10:30		Coffee break
11:00		Clinical session Gastro-intestinal tumours I    Chair: D. Sebag-Montefiore, UK
		Systemic treatment in advanced colon cancer (including adjuvant therapy)    E. van Cutsem, BE Management of rectal cancer (surgery and radiotherapy) D. Sebag-Montefiore, UK Systemic treatment in early and advanced gastric cancer A. Cervantes, ES Discussion
13:00		Lunch
14:00		Clinical session Gastro-intestinal tumours II    Chair: D. Sebag-Montefiore, UK
		Pancreatic Cancer    R. Popescu, CH   Discussion
14:30		Tumour board Gastro-intestinal tumours     A. Cervantes, ES -  D. Sebag-Montefiore, UK - E. van Cutsem, BE - R. Popescu, CH
15:30		Spotlight session Biosimilars    G. Curigliano, IT
16:00		Spotlight session Fertility preservation / Cancer and pregnancy    F.A. Peccatori, IT
18:30		Aperitif with the expert GI cancers
19:00		Special evening

 

 16 March

8:30		PARALLEL SESSIONS
		Case presentations by participants N. Pavlidis, GR - R.A. Stahel, CH - R. Popescu, CH
10:00		Clinical session Breast cancer I    Chair: G. Curigliano, IT
		(Neo)Adjuvant chemotherapy and biological agents     G. Curigliano, IT   (Neo)Adjuvant endocrine therapy     O. Pagani, CH
11:00		Coffee break
11:30		Clinical session Breast cancer II    Chair: O. Pagani, CH
		Current controversies and challenges in breast surgery     W. Gatzemeier, IT   Management of HER-2+ and triple negative advanced breast cancer     G. Curigliano, IT Management of ER+ advanced breast cancer     O. Pagani, CH   Essentials and news in breast cancer radiation therapy    J. Bernier, CH   Discussion
13:00		Lunch
13:45		Tumour board Breast cancer     G. Curigliano, IT - O. Pagani, CH - W. Gatzemeier, IT - J. Bernier, CH
14:45		Clinical session Head and neck cancer I    Chair: J.B. Vermorken, BE
		Prognostic factors and surgical approach    A. Dietz, DE   Radiotherapy    J. Bernier, CH      Discussion
15:45		Coffee break
16:15		Clinical session Head and neck cancer II    Chair: J.B. Vermorken, BE
		Systemic therapy and radio- chemo-therapy    J.B. Vermorken, BE
17:00		Tumour board Head & Neck cancer  J.B. Vermorken, BE - J. Bernier, CH - A. Dietz, DE
18:30		Aperitif with the expert Breast, H&N, Gynaecological cancers
19:30		Dinner

 

 17 March

8:30		Clinical session Gynaecological cancers    Chair: J.B. Vermorken, BE
		Ovarian cancer    J.B. Vermorken, BE Cervical and endometrial cancers C. Sessa, CH Discussion
10:00		Tumour board Gynaecological cancers     J.B. Vermorken, BE - C. Sessa, CH
10:30		Coffee break
10:00		Learning assessment test
12:00		Closing remarks